Keyphrases
Clinical Outcomes
100%
Factor Level
100%
Vascular Endothelial Growth Factor
100%
Early Change
100%
First-line Therapy
100%
Aggressive non-Hodgkin Lymphoma
100%
Serum interleukin-6
100%
Interleukin-6
42%
Clinical Impact
28%
Serum Levels
28%
Overall Survival
28%
Clinical Response
14%
Inflammatory Cytokines
14%
Multivariate Analysis
14%
Serial Measurements
14%
Response Rate
14%
First Week
14%
Complete Remission
14%
Serum Samples
14%
Lines of Evidence
14%
New Treatment Options
14%
Clinical Parameters
14%
Lymphoma
14%
Biological Processes
14%
Enzyme-linked Immunosorbent Assay (ELISA)
14%
Cyclophosphamide
14%
Low-risk Patients
14%
Interleukin-6 Levels
14%
Prognostic Information
14%
First Cycle
14%
Clinical Prognostic Factors
14%
Non-Hodgkin Lymphoma
14%
Prognostic Indicator
14%
Prednisone
14%
Doxorubicin
14%
Newly Diagnosed Patients
14%
Early Recognition
14%
Tumor-host Interactions
14%
Commercial Enzymes
14%
Serial Monitoring
14%
Chemotherapy Initiation
14%
CHOP Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Interleukin 6
100%
Vasculotropin
100%
Nonhodgkin Lymphoma
100%
Cytokine
25%
Overall Survival
25%
Neoplasm
12%
Remission
12%
Prednisone
12%
Enzyme-Linked Immunosorbent Assay
12%
Chemotherapy
12%
Cyclophosphamide
12%
Doxorubicin
12%
Vincristine
12%
Biochemistry, Genetics and Molecular Biology
Vascular Endothelial Growth Factor
100%
Interleukin 6
100%
Blood Level
25%
Overall Survival
25%
Enzyme
12%
Cytokine
12%
Multivariate Analysis
12%
Biological Phenomena and Functions Concerning the Entire Organism
12%
Inflammatory Cytokine
12%
Cyclophosphamide
12%
Prednisone
12%
Doxorubicin
12%
Immunology and Microbiology
Interleukin 6
100%
Vasculotropin
100%
Blood Level
25%
Overall Survival
25%
Cytokine
12%
Inflammatory Cytokine
12%
Enzyme-Linked Immunosorbent Assay
12%
Cyclophosphamide
12%
Biological Phenomena and Functions Concerning the Entire Organism
12%
Prednisone
12%